Literature DB >> 34421142

Long Acting Injectables and their Correlation with Subjectivity in Schizophrenia Spectrum Disorder.

Ivano Caselli1, Alessandra Gasparini1, Marta Ielmini1, Giulia Lucca1, Stefano Amorosi1, Nicola Poloni1, Camilla Callegari1.   

Abstract

Nowadays, mental illness can no longer be considered as a mere list of symptoms corresponding to localized brain dysfunctions but rather as a disturbance of the patient's subjectivity. Thus, a solid, qualitative study of patients' subjectivity could represent a useful tool in the complex evaluation of efficacy of pharmacotherapy in schizophrenic persons. In this perspective, authors performed a phenomenological oriented investigation on 49 patients, diagnosed with schizophrenia spectrum disorder, who were receiving long-acting injectable (LAI) antipsychotic therapy. From data analysis, authors found a positive correlation between general psychopathology and the use of LAI antipsychotic therapies. The present study highlighted the necessity of a careful investigation of patients' subjectivity in a phenomenological way as an irreducible part of both psychopathological and psychopharmacological matters.
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  long-acting injectables; phenomenology; psychopathology; schizophrenia; subjectivity

Mesh:

Substances:

Year:  2021        PMID: 34421142      PMCID: PMC8374925     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  23 in total

1.  EASE: Examination of Anomalous Self-Experience.

Authors:  Josef Parnas; Paul Møller; Tilo Kircher; Jørgen Thalbitzer; Lennart Jansson; Peter Handest; Dan Zahavi
Journal:  Psychopathology       Date:  2005-09-20       Impact factor: 1.944

2.  A single case report of recurrent surgery for chronic back pain and its implications concerning a diagnosis of Münchausen syndrome.

Authors:  C Callegari; P Bortolaso; S Vender
Journal:  Funct Neurol       Date:  2006 Apr-Jun

3.  [Metabolic side effects of second generation antipsychotics in drug-naïve patients: a preliminary study].

Authors:  Marcello Diurni; Federico Baranzini; Chiara Costantini; Nicola Poloni; Simone Vender; Camilla Callegari
Journal:  Riv Psichiatr       Date:  2009 May-Jun       Impact factor: 1.911

4.  Twenty years of Lithium pharmacogenetics: A systematic review.

Authors:  R Pagani; A Gasparini; M Ielmini; I Caselli; N Poloni; M Ferrari; F Marino; C Callegari
Journal:  Psychiatry Res       Date:  2019-05-23       Impact factor: 3.222

5.  The two-syndrome concept: origins and current status.

Authors:  T J Crow
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

6.  Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia.

Authors:  Marco Ferrari; Emilio Bolla; Paola Bortolaso; Camilla Callegari; Nicola Poloni; Sergio Lecchini; Simone Vender; Franca Marino; Marco Cosentino
Journal:  Psychiatry Res       Date:  2012-08-16       Impact factor: 3.222

Review 7.  The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.

Authors:  Seiya Miyamoto; W Wolfgang Fleischhacker
Journal:  Curr Treat Options Psychiatry       Date:  2017-04-19

8.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15

9.  A naturalistic study on the relationship among resilient factors, psychiatric symptoms, and psychosocial functioning in a sample of residential patients with psychosis.

Authors:  Nicola Poloni; Daniele Zizolfi; Marta Ielmini; Roberto Pagani; Ivano Caselli; Marcello Diurni; Anna Milano; Camilla Callegari
Journal:  Psychol Res Behav Manag       Date:  2018-04-10

10.  The utility of pharmacogenetic testing to support the treatment of bipolar disorder.

Authors:  Marta Ielmini; Nicola Poloni; Ivano Caselli; Jordi Espadaler; Miquel Tuson; Alessandro Grecchi; Camilla Callegari
Journal:  Pharmgenomics Pers Med       Date:  2018-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.